Cargando…

Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study

BACKGROUNDS: GALLIUM is a global phase III study that demonstrated significant improvements in progression-free survival (PFS) for obinutuzumab plus chemotherapy (G-chemo) vs. rituximab plus chemotherapy (R-chemo) in previously untreated patients with follicular lymphoma (FL). This study aimed to re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Xiaonan, Song, Yuqin, Shi, Yuankai, Zhang, Qingyuan, Guo, Wei, Wu, Gang, Li, Junmin, Feng, Jifeng, Kinkolykh, Anastasiia, Knapp, Andrea, Lin, Tongyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869628/ https://www.ncbi.nlm.nih.gov/pubmed/35194005 http://dx.doi.org/10.1097/CM9.0000000000001737

Ejemplares similares

Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma
por: Davies, Andrew, et al.
Publicado: (2020)

Impact of obinutuzumab alone and in combination for follicular lymphoma
por: Sarraf Yazdy, Maryam, et al.
Publicado: (2017)

The clinical development of obinutuzumab for the treatment of follicular lymphoma
por: Ma, Barbara, et al.
Publicado: (2017)

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma
por: Grigg, Andrew, et al.
Publicado: (2017)

Pharmacokinetics of obinutuzumab in Chinese patients with B‐cell lymphomas
por: Zhai, John, et al.
Publicado: (2017)

Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
por: Herold, Michael, et al.
Publicado: (2022)

Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression
por: Seymour, John F., et al.
Publicado: (2019)

GALLIUM trial: the tortoise (rituximab) and the hare (obinutuzumab) race
por: García-Muñoz, Ricardo, et al.
Publicado: (2019)

Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab‐refractory follicular lymphoma patients in the GADOLIN phase III study
por: Gibiansky, Ekaterina, et al.
Publicado: (2019)

P1080: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY
por: Trotman, Judith, et al.
Publicado: (2023)

Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial
por: Qin, Yan, et al.
Publicado: (2018)

Prolonged COVID-19 in an Immunocompromised Patient Treated with Obinutuzumab and Bendamustine for Follicular Lymphoma
por: Ueda, Yayoi, et al.
Publicado: (2022)

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
por: Spencer, Scott J, et al.
Publicado: (2021)

Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model
por: Decaup, E, et al.
Publicado: (2013)

Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first‐line immunochemotherapy
por: Jamois, Candice, et al.
Publicado: (2019)

Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma
por: Claustre, Gwladys, et al.
Publicado: (2022)

Correction Notice: Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
Publicado: (2022)

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
por: Townsend, William, et al.
Publicado: (2023)

Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial
por: Morschhauser, Franck, et al.
Publicado: (2021)

SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
por: Stathis, Anastasios, et al.
Publicado: (2022)

Prolonged SARS‐CoV‐2 infection during obinutuzumab and bendamustine treatment for follicular lymphoma: A case report
por: Kambe, Ryosuke, et al.
Publicado: (2023)

A Favorable Outcome of Grade 3 Follicular Lymphoma Treated With Surgery and Obinutuzumab Combined With Chemotherapy: A Case Report and Literature Review
por: Mekheal, Erinie, et al.
Publicado: (2022)

Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab
por: Franceschini, Erica, et al.
Publicado: (2023)

Prolonged SARS-CoV-2 Infection and Organizing Pneumonia in a Patient with Follicular Lymphoma, Treated with Obinutuzumab—Challenging Recognition and Treatment
por: Łyżwa, E., et al.
Publicado: (2023)

PB2273: EFFICACY OF OBINUTUZUMAB - BASED REGIMENS IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: A RETROSPECTIVE OBSERVATIONAL SINGLE-CENTER STUDY
por: Ridova, Nevenka, et al.
Publicado: (2023)

Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study
por: Stilgenbauer, Stephan, et al.
Publicado: (2018)

Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma: An Evidence Review Group Evaluation of the NICE Single Technology Appraisal
por: Thielen, Frederick W., et al.
Publicado: (2018)

Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis
por: Canales, Miguel A., et al.
Publicado: (2023)

A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
por: Sehn, Laurie H., et al.
Publicado: (2020)

Hexaaquagallium(III) trinitrate trihydrate
por: Hendsbee, Arthur D., et al.
Publicado: (2009)

P1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL-102)
por: Hamadani, M., et al.
Publicado: (2022)

PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL
por: Qiu, Lihua, et al.
Publicado: (2023)

Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups
por: Batlevi, Connie L., et al.
Publicado: (2020)

Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial
por: Zhu, Jun, et al.
Publicado: (2022)

Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate–High Risk: A Cost-Effectiveness Analysis
por: Bellone, Marco, et al.
Publicado: (2021)

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
por: Moreno, Carol, et al.
Publicado: (2022)

PB2269: PI3KΔ INHIBITOR LINPERLISIB FOR ELDERLY PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL
por: Sun, Xiuhua, et al.
Publicado: (2023)

Follicular lymphoma subgroups with and without t(14;18) differ in their N-glycosylation pattern and IGHV usage
por: Leich, Ellen, et al.
Publicado: (2021)

catena-Poly[[gallium(III)-bis[μ-D/l-tartrato(2−)]-gallium(III)-di-μ-hydroxido] dihydrate]
por: Liu, Xiaojing, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_9mih4cmj17arcuc636rv4a1ret